STAT3/HDAC-IN-2

STAT3/HDAC-IN-2

• UNSPSC Description: STAT3/HDAC-IN-2 (compound 18) is a dual inhibitor of STAT3 and HDAC, inducing autophagy and apoptosis. STAT3/HDAC-IN-2 is an amphiphilic hydroxamic acid hybrid based on the natural product isopropanol lactone (IAL) and is a nanoscale anticancer agent. STAT3/HDAC-IN-2 can self-assemble in water to form nanoparticles, which have higher tumor tissue accumulation, cellular uptake and anticancer properties compared to the free state[1].
• Target Antigen: HDAC; STAT
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage;Epigenetics;JAK/STAT Signaling;Stem Cell/Wnt
• Field of Research: cancer
• Assay Protocol: https://www.medchemexpress.com/stat3-hdac-in-2.html
• Smiles: O=C(NO)/C=C/C1=CC=C(C(N[C@H](C)C(O[C@H]2C([C@@](C[C@@](C(C(O3)=O)=C)([H])[C@@]3([H])C4)([H])[C@]4(C)CC2)=C)=O)=O)C=C1
• Molecular Weight: 508.56
• References & Citations: [1]Isoalantolactone/hydroxamic acid hybrids as potent dual STAT3/HDAC inhibitors and self-assembled nanoparticles for cancer therapy
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported